Literature DB >> 30847504

Determination of melphalan in human plasma by UPLC-UV method.

Liusheng Huang1, Vincent Cheah2, Danna Chan3, Florence Marzan2, Christopher C Dvorak4, Francesca T Aweeka2, Janel Long-Boyle3.   

Abstract

It is desirable to develop a fast method for quantification of melphalan due to its instability. Here we report a method for quantification of melphalan (MPL) in human plasma using a UPLC-PDA system. Briefly, 50 µL plasma sample was mixed with 25 µL internal standard (2500 ng/mL acetylmelphalan in methanol) and 25 µL 20% trichloroacetic acid, and centrifuged at 21,000 g (15,000 rpm) at 4 °C for 3 min. The supernatant (5 µL) was injected onto an Acquity™ BEH C18 LC column (2.1 × 50 mm, 1.7 µm) and eluted with 25 mM NH4AC (pH 4.7)-acetonitrile in a gradient mode at a flow rate of 0.6 mL/min. The column kept at 40 ± 5 °C and the autosampler kept at 4 ± 5 °C. The detector set at 261 nm, and sampling rate was 40points/sec. The retention times were typically 2.11 min for melphalan and 2.38 min for the internal standard. Total run time is 4 min per sample. Calibration range was 100-40,000 ng/mL. The lower limit of quantification was 100 ng/mL. The method was validated based on the FDA guidelines, and applied to a clinical pharmacokinetic study in pediatric patients.

Entities:  

Keywords:  Melphalan; Pediatric; Pharmacokinetic.; Plasma; UPLC–UV

Mesh:

Substances:

Year:  2019        PMID: 30847504      PMCID: PMC6490959          DOI: 10.1007/s00280-019-03786-6

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

Review 1.  Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.

Authors:  A G Hall; M J Tilby
Journal:  Blood Rev       Date:  1992-09       Impact factor: 8.250

2.  High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

Authors:  Christa E Nath; Judith Trotman; Campbell Tiley; Peter Presgrave; Douglas Joshua; Ian Kerridge; Yiu Lam Kwan; Howard Gurney; Andrew J McLachlan; John W Earl; Ian Nivison-Smith; Lihua Zeng; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2016-04-27       Impact factor: 4.335

3.  Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Kana Mizuno; Min Dong; Tsuyoshi Fukuda; Sharat Chandra; Parinda A Mehta; Scott McConnell; Elias J Anaissie; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

4.  Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Authors:  Christa E Nath; Peter J Shaw; Judith Trotman; Lihua Zeng; Stephen B Duffull; Gareth Hegarty; Andrew J McLachlan; Howard Gurney; Ian Kerridge; Yiu Lam Kwan; Peter Presgrave; Campbell Tiley; Douglas Joshua; John Earl
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

5.  Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2007-02-23       Impact factor: 4.335

6.  High-performance liquid chromatographic assay for melphalan in human plasma. Application to pharmacokinetic studies.

Authors:  F Pinguet; J M Joulia; P Martel; P Y Grosse; C Astre; F Bressolle
Journal:  J Chromatogr B Biomed Appl       Date:  1996-11-08

7.  Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

8.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma.

Authors:  Liusheng Huang; Florence Marzan; Anura L Jayewardene; Patricia S Lizak; Xiaohua Li; Francesca T Aweeka
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-12-24       Impact factor: 3.205

10.  Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.

Authors:  Liusheng Huang; Patricia Lizak; Christopher C Dvorak; Francesca Aweeka; Janel Long-Boyle
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-05-02       Impact factor: 3.205

View more
  1 in total

1.  Vitamin E Oil Incorporated Liposomal Melphalan and Simvastatin: Approach to Obtain Improved Physicochemical Characteristics of Hydrolysable Melphalan and Anticancer Activity in Combination with Simvastatin Against Multiple Myeloma.

Authors:  Unnam Sambamoorthy; Arehalli S Manjappa; Bhanoji Rao Muddana Eswara; Arun Kumar Sanapala; Naidu Nagadeepthi
Journal:  AAPS PharmSciTech       Date:  2021-12-14       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.